Moderna announced first participants in each age cohort dosed in phase 2 study of mRNA vaccine against novel Coronavirus
On May 29, 2020, Moderna announced the first participants in each age cohort had been dosed in the…
			On May 29, 2020, Moderna announced the first participants in each age cohort had been dosed in the…
			On May 28, 2020, Biogen and the Lemelson-MIT Program (LMIT) at the Massachusetts Institute of Technology announced the…
			On May 18, 2020, Moderna announced positive interim clinical data of mRNA-1273, its vaccine candidate against novel coronavirus…
			On May 13, 2020, the Massachusetts Consortium on Pathogen Readiness (MassCPR), a multi-institutional initiative convened by Harvard Medical…
			On May 12, 2020, Moderna announced the U.S. Food and Drug Administration (FDA had granted Fast Track designation…
			On May 12, 2020, the Broad Instituteメs Drug Repurposing Hub announced that it had opened its repository of…
			On May 5, 2020, Massachusetts Eye and Ear and Massachusetts General Hospital (MGH), members of Mass General Brigham,…
			On May 5, 2020, a team of researchers at the McGovern Institute for Brain Research at MIT, the…
			On May 1, 2020, Moderna and Lonza announced a 10-year strategic collaboration agreement to enable larger scale manufacture…
			On Apr. 27, 2020, Yield10 Bioscience announced it has obtained a positive response from USDA-APHIS’s Biotechnology Regulatory Services…
			On Apr. 27, 2020, Moderna announced it had submitted an Investigational New Drug application to the U.S. Food…
			On Apr. 22, 2020, researchers at Massachusetts Institute of Technology (MIT); the Ragon Institute of MGH, and Harvard…
			On Apr. 16, 2020, Biogen, Broad Institute of MIT and Harvard, and Partners HealthCare announced a consortium that…
			On Apr. 16, 2020, Moderna announced an agreement for a commitment of up to $483 million from the…
			On Apr. 16, 2020, a team of researchers at the McGovern Institute for Brain Research at MIT, the…
			On Apr. 7, 2020, Harvard University, Massachusetts Institute of Technology, and Stanford University announced they had established and…
			On Apr. 6, 2020, Emory’s Vaccine and Treatment Evaluation Unit (VTEU) announced its participation in a clinical trial…
			On Apr. 5, 2020, updated COVID-19 estimates from the Institute for Health Metrics and Evaluation (IHME) found that…
			On Apr. 2, 2020, BioAegis Therapeutics announced that it was preparing to evaluate plasma gelsolin replacement in severe…
			On Mar. 26, 2020, working in partnership with the Commonwealth of Massachusetts, Massachusetts State Public Health Laboratory, and…
			On Mar. 25, 2020, a mobility and epidemiological study from a global consortium of researchers, led by the…
			On Mar. 24, 2020, the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern announced it had joined…
			On Mar. 23 2020, The Priestley Medal was awarded to JoAnne Stubbe by the American Chemical Society “to…
			On Mar. 23, 2020, Harvard Bioscience announced that it had launched an innovative technology – known as Accumulated…
			On Mar. 16, 2020, Moderna announced that the first participant had been dosed in the Phase 1 study…
			On Mar. 3, 2020, Moderna announced that enrollment was complete for all three dose cohorts of the Phase…
			On Mar. 2, 2020, Boston’s top infectious disease researchers, including scientists from Boston University’s National Emerging Infectious Diseases…
			On Mar. 2, 2020, Innovation Pharma provided the scientific rationale and clinical development perspectives for Brilacidin, the Company’s…
			On Feb. 24, 2020, Moderna announced it had released the first batch of mRNA-1273, the Company’s vaccine against…
			On Feb. 20, 2020, using a machine-learning algorithm, researchers at MIT and the Broad Institute of MIT and…